What are the recommended fluvoxamine dosing regimens for adults with OCD or major depressive disorder, for children aged 8 and older, and what dose adjustments are needed for hepatic impairment?

Fluvoxamine Dosing Recommendations

Adult Dosing for OCD and Major Depressive Disorder

Start fluvoxamine at 50 mg once daily at bedtime in adults, then increase by 50 mg increments every 4–7 days as tolerated up to a maximum of 300 mg/day, with doses above 100 mg/day split into two divided doses (larger dose at bedtime). 1

Titration Schedule

• Initial dose: 50 mg once daily at bedtime 1
• Titration: Increase in 50 mg increments every 4–7 days based on tolerability 1
• Therapeutic range: 100–300 mg/day for OCD, established in controlled trials 1
• Maximum dose: 300 mg/day 1
• Divided dosing: Total daily doses exceeding 100 mg should be split into two doses, with the larger dose given at bedtime 1

Clinical Response Timeline

• Mean reductions of 4–5 units on the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) were observed in adults with OCD receiving fluvoxamine versus 2 units with placebo 1
• Response rates of 38–52% have been documented with fluvoxamine compared to 0–18% with placebo in OCD trials 2
• Therapeutic effect typically becomes evident by week 6, with maximal benefit by week 12 3

---

Pediatric Dosing (Ages 8–17 Years)

Begin fluvoxamine at 25 mg once daily at bedtime in children and adolescents, then increase by 25 mg increments every 4–7 days as tolerated, with maximum doses of 200 mg/day for children up to age 11 and 300 mg/day for adolescents. 1

Age-Specific Titration

• Starting dose: 25 mg once daily at bedtime 1
• Titration: Increase in 25 mg increments every 4–7 days 1
• Children ≤11 years: Maximum 200 mg/day 1
• Adolescents 12–17 years: May titrate up to adult maximum of 300 mg/day 1
• Divided dosing: Total daily doses exceeding 50 mg should be split into two doses, with the larger dose at bedtime 1

Gender Considerations in Children

• Female children (ages 6–11): Therapeutic effect may be achieved at lower doses due to significantly higher drug exposure 1
• Female children showed AUC and Cmax values 1.5- to 2.7-fold higher than male children 1
• No gender differences were observed in adolescents 1

Pediatric Efficacy Data

• Mean reductions of approximately 6 units on the Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS) with fluvoxamine versus 3 units with placebo 1
• 42% of pediatric patients were responders (≥25% reduction in CY-BOCS) compared to 26% with placebo 4
• Rapid onset of action with significant differences from placebo observed as early as week 1 4

---

Hepatic Impairment Dosing

In patients with hepatic impairment or elderly patients, initiate fluvoxamine at a lower starting dose and titrate more slowly due to 30–50% reduced clearance. 1

Pharmacokinetic Changes

• Hepatic dysfunction decreases fluvoxamine clearance by approximately 30% 1
• Elderly patients (ages 66–73) show 40% higher maximum plasma concentrations and 50% reduced clearance compared to younger adults 1
• Elimination half-life increases from 13.6–15.6 hours in young adults to 17.4–25.9 hours in elderly patients 1

Dosing Strategy

• Start at a reduced dose (consider 25 mg daily) 1
• Titrate slowly with longer intervals between dose increases 1
• Monitor closely for adverse effects, particularly nausea, somnolence, and drug interactions 1

Renal Impairment

• No dose adjustment is required for renal impairment 1
• Mean minimum plasma concentrations in patients with creatinine clearance 5–45 mL/min were comparable after 4 and 6 weeks, indicating no drug accumulation 1

---

Important Safety Considerations

Drug Interactions

• Fluvoxamine is a potent inhibitor of CYP1A2 and moderate inhibitor of CYP2C19, CYP2C9, and CYP3A4 3, 2
• Weak inhibitor of CYP2D6 relative to other SSRIs 2
• Conduct comprehensive medication review before initiating therapy due to high potential for drug-drug interactions 3

Common Adverse Effects

• Nausea is the most common adverse effect, occurring in >10% of patients 2
• Other frequent effects include somnolence, asthenia, headache, dry mouth, and insomnia 2
• In pediatric trials, insomnia and asthenia had placebo-adjusted rates >10% 4

Discontinuation

• Taper gradually rather than stopping abruptly to prevent discontinuation syndrome 1
• Discontinuation symptoms include dizziness, nausea, paresthesias, anxiety, and flu-like complaints 3
• Both fluvoxamine and sertraline have relatively short half-lives, necessitating careful tapering 3

Monitoring During Pregnancy

• When treating pregnant women during the third trimester, carefully weigh risks versus benefits 1
• Consider tapering fluvoxamine in the third trimester, as neonates exposed late in pregnancy may develop complications requiring prolonged hospitalization 1

---

Off-Label High-Dose Considerations

For treatment-resistant OCD, fluvoxamine doses up to 650 mg/day (sertraline equivalent dose) have been used safely in specialized settings, though the FDA-approved maximum remains 300 mg/day. 5, 6

• A retrospective study of 105 OCD patients treated with off-label high-dose SRIs for ≥6 months found fluvoxamine >300 mg/day to be safe and well-tolerated 5
• Side effects did not differ significantly between dosing groups (SED ≤200 mg/day, 201–400 mg/day, and 401–650 mg/day) 5
• One case report documented remission with 600 mg/day fluvoxamine in treatment-resistant OCD, maintained for 3 months 6
• This approach should only be considered after standard-dose trials have failed and requires close monitoring 5, 6